68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)

This study uses a special type of PET scan (called 68Ga-FAPI-46) to see whether it can predict how well triple-negative breast cancer (an aggressive subtype of breast cancer) will respond to chemotherapy plus immunotherapy given before surgery. **You may be eligible if...** - You are a female aged 18 or older - You have been newly diagnosed with triple-negative breast cancer (TNBC) that has not been treated yet and has not spread to distant organs - Your doctor recommends pre-surgery treatment with chemotherapy plus pembrolizumab (an immunotherapy) - You have a measurable tumor on imaging - You are covered by health insurance **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have previously received immunotherapy (anti-PD-1 or anti-PD-L1) - You have a condition that prevents you from receiving the standard treatment combination - You have already had distant metastases identified on staging scans Talk to your doctor to see if this trial is right for you.